FDA squashes accelerated hopes for Eli Lilly’s Alzheimer’s drug as agency asks for more data
The FDA flashed a red light on Eli Lilly’s investigational Alzheimer’s drug donanemab, spurning hopes of two new medications for the disease this month …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
